Paraoxonase 1 status is a major Janus-faced component of mild and moderate acute ischemic stroke and consequent disabilities
Authors:
- Francis F. BrinholiFBFrancis F. Brinholi
- Ana Paula MichelinAMAna Paula Michelin
- Andressa K. MatsumotoAMAndressa K. Matsumoto
- Laura de O. SemeãoLSLaura de O. Semeão
- Abbas F. AlmullaAbbas F. Almulla
- Thitiporn SupasitthumrongTSThitiporn Supasitthumrong
- Chavit TunvirachaisakulCTChavit Tunvirachaisakul
- Decio S. BarbosaDBDecio S. Barbosa
- Michael MaesMMMichael Maes
Preprint
Abstract
Aims This study aims to examine the associations between paraoxonase 1 (PON)1 status and acute ischemic stroke (AIS) and consequent disabilities. Methods This study recruited 122 patients with AIS and 40 healthy controls and assessed the Q192R gene variants, arylesterase (AREase) and chloromethyl phenylacetate (CMPAase) activities, and high-density lipoprotein cholesterol (HDL) in baseline conditions. AREase and CMPAase were measured 3 months later. The National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin score (mRS) were assessed at baseline and 3 and 6 months later. Results Reduced CMPAase and increased AREase activities are significantly associated with AIS and mRS and NIHSS scores (baseline and 3 and 6 months later). The best predictor of AIS/disabilities was a decrease in the z-unit-based composite zCMPAase-zAREase score. Serum high density lipoprotein cholsterol (HDL) was significantly correlated with CMPAase, but not AREase, activity and a lowered zCMPAase+zHDL score was the second best predictor of AIS/disabilities. Regression analysis showed that 34.7% of the variance in baseline NIHSS was explained by zCMPAase-zAREase and zCMPAase+zHDL composites, HDL, and hypertension. Neural network analysis showed that stroke was differentiated from controls with an area under the ROC curve of 0.975 using both new composite scores, PON1 status, hypertension, dyslipidemia, previous stroke as body mass index. The PON1 Q192R genotype has many significant direct and mediated effects on AIS/disabilities, however, its overall effect was not significant. Discussion PON1 status and the CMPAase-HDL complex play key roles in AIS and its disabilities at baseline and 3 and 6 months later.Keywords
All Related Versions
This publication has 77 references indexed in Scilit:
- Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysisGenetics in Medicine, 2010
- Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysisEuropean Journal of Epidemiology, 2010
- Paraoxonase 1 Status as a Risk Factor for Disease or Exposure2009
- Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular RiskJAMA, 2008
- Dyslipidaemia as a predictor of hypertension in middle-aged menEuropean Heart Journal, 2008
- Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in KoreansBiochemical and Biophysical Research Communications, 2007
- Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical TrialsStroke, 2007
- Age and National Institutes of Health Stroke Scale Score Within 6 Hours After Onset Are Accurate Predictors of Outcome After Cerebral IschemiaStroke, 2004
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Recovery of motor function after stroke.Stroke, 1988